**Core Concept**
The question pertains to the treatment of Herpes Simplex Virus (HSV) infections, specifically in cases where the virus is resistant to acyclovir, a first-line antiviral medication. The underlying principle being tested is the pharmacological mechanism of antiviral resistance and the appropriate treatment strategy for resistant viral strains.

**Why the Correct Answer is Right**
Resistance to acyclovir typically arises due to mutations in the viral thymidine kinase (TK) enzyme or the viral DNA polymerase. To overcome this resistance, an alternative antiviral medication that does not rely on these enzymes for activation is required. Foscarnet is a potent antiviral medication that directly inhibits viral DNA polymerase, making it effective against acyclovir-resistant HSV strains.

**Why Each Wrong Option is Incorrect**
**Option A:** Valaciclovir - While valaciclovir is an effective antiviral medication, it is a prodrug that requires activation by the viral TK enzyme, making it less effective against acyclovir-resistant strains.

**Option B:** Cidofovir - Although cidofovir is an antiviral medication, it is primarily used to treat cytomegalovirus (CMV) infections and is not the preferred treatment for acyclovir-resistant HSV.

**Option C:** Ribavirin - Ribavirin is an antiviral medication used to treat various viral infections, but it is not effective against HSV and is not indicated for the treatment of acyclovir-resistant HSV.

**Clinical Pearl / High-Yield Fact**
In cases of acyclovir-resistant HSV, it is essential to promptly initiate alternative antiviral therapy to prevent severe complications and reduce the risk of transmission.

**Correct Answer:** C. Foscarnet. Foscarnet is the correct answer as it is the drug of choice for treating acyclovir-resistant HSV infections.